Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms
Myeloproliferative neoplasms (MPN) are rare hematologic disorders characterized by clonal hematopoiesis. Familial clustering is observed in a subset of cases, with a notable proportion exhibiting heterozygous germline mutations in DNA double-strand break repair genes (e.g., ). We investigated the th...
Saved in:
| Published in: | International journal of molecular sciences Vol. 24; no. 24; p. 17560 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Switzerland
MDPI AG
16-12-2023
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Myeloproliferative neoplasms (MPN) are rare hematologic disorders characterized by clonal hematopoiesis. Familial clustering is observed in a subset of cases, with a notable proportion exhibiting heterozygous germline mutations in DNA double-strand break repair genes (e.g.,
). We investigated the therapeutic potential of targeting
haploinsufficiency alongside the
V617F driver mutation. We assessed the efficacy of combining the PARP inhibitor olaparib with interferon-alpha (IFNα) in CRISPR/Cas9-engineered
V617F-positive 32D cells. Olaparib treatment induced a higher number of DNA double-strand breaks, as demonstrated by γH2AX analysis through Western blot (
= 0.024), flow cytometry (
= 0.013), and confocal microscopy (
= 0.071). RAD51 foci formation was impaired in
cells compared to
cells, indicating impaired homologous recombination repair due to
haploinsufficiency. Importantly, olaparib enhanced apoptosis while diminishing cell proliferation and viability in
cells compared to
cells. These effects were further potentiated by IFNα. Olaparib induced interferon-stimulated genes and increased endogenous production of IFNα in
cells. These responses were abrogated by STING inhibition. In conclusion, our findings suggest that the combination of olaparib and IFNα presents a promising therapeutic strategy for MPN patients by exploiting the synthetic lethality between germline
mutations and the
V617F MPN driver mutation. |
|---|---|
| AbstractList | Myeloproliferative neoplasms (MPN) are rare hematologic disorders characterized by clonal hematopoiesis. Familial clustering is observed in a subset of cases, with a notable proportion exhibiting heterozygous germline mutations in DNA double-strand break repair genes (e.g., BRCA1). We investigated the therapeutic potential of targeting BRCA1 haploinsufficiency alongside the JAK2V617F driver mutation. We assessed the efficacy of combining the PARP inhibitor olaparib with interferon-alpha (IFNα) in CRISPR/Cas9-engineered Brca1+/− Jak2V617F-positive 32D cells. Olaparib treatment induced a higher number of DNA double-strand breaks, as demonstrated by γH2AX analysis through Western blot (p = 0.024), flow cytometry (p = 0.013), and confocal microscopy (p = 0.071). RAD51 foci formation was impaired in Brca1+/− cells compared to Brca1+/+ cells, indicating impaired homologous recombination repair due to Brca1 haploinsufficiency. Importantly, olaparib enhanced apoptosis while diminishing cell proliferation and viability in Brca1+/− cells compared to Brca1+/+ cells. These effects were further potentiated by IFNα. Olaparib induced interferon-stimulated genes and increased endogenous production of IFNα in Brca1+/− cells. These responses were abrogated by STING inhibition. In conclusion, our findings suggest that the combination of olaparib and IFNα presents a promising therapeutic strategy for MPN patients by exploiting the synthetic lethality between germline BRCA1 mutations and the JAK2V617F MPN driver mutation. Myeloproliferative neoplasms (MPN) are rare hematologic disorders characterized by clonal hematopoiesis. Familial clustering is observed in a subset of cases, with a notable proportion exhibiting heterozygous germline mutations in DNA double-strand break repair genes (e.g., BRCA1). We investigated the therapeutic potential of targeting BRCA1 haploinsufficiency alongside the JAK2V617F driver mutation. We assessed the efficacy of combining the PARP inhibitor olaparib with interferon-alpha (IFNα) in CRISPR/Cas9-engineered Brca1+/− Jak2V617F-positive 32D cells. Olaparib treatment induced a higher number of DNA double-strand breaks, as demonstrated by γH2AX analysis through Western blot (p = 0.024), flow cytometry (p = 0.013), and confocal microscopy (p = 0.071). RAD51 foci formation was impaired in Brca1+/− cells compared to Brca1+/+ cells, indicating impaired homologous recombination repair due to Brca1 haploinsufficiency. Importantly, olaparib enhanced apoptosis while diminishing cell proliferation and viability in Brca1+/− cells compared to Brca1+/+ cells. These effects were further potentiated by IFNα. Olaparib induced interferon-stimulated genes and increased endogenous production of IFNα in Brca1+/− cells. These responses were abrogated by STING inhibition. In conclusion, our findings suggest that the combination of olaparib and IFNα presents a promising therapeutic strategy for MPN patients by exploiting the synthetic lethality between germline BRCA1 mutations and the JAK2V617F MPN driver mutation. Myeloproliferative neoplasms (MPN) are rare hematologic disorders characterized by clonal hematopoiesis. Familial clustering is observed in a subset of cases, with a notable proportion exhibiting heterozygous germline mutations in DNA double-strand break repair genes (e.g., ). We investigated the therapeutic potential of targeting haploinsufficiency alongside the V617F driver mutation. We assessed the efficacy of combining the PARP inhibitor olaparib with interferon-alpha (IFNα) in CRISPR/Cas9-engineered V617F-positive 32D cells. Olaparib treatment induced a higher number of DNA double-strand breaks, as demonstrated by γH2AX analysis through Western blot ( = 0.024), flow cytometry ( = 0.013), and confocal microscopy ( = 0.071). RAD51 foci formation was impaired in cells compared to cells, indicating impaired homologous recombination repair due to haploinsufficiency. Importantly, olaparib enhanced apoptosis while diminishing cell proliferation and viability in cells compared to cells. These effects were further potentiated by IFNα. Olaparib induced interferon-stimulated genes and increased endogenous production of IFNα in cells. These responses were abrogated by STING inhibition. In conclusion, our findings suggest that the combination of olaparib and IFNα presents a promising therapeutic strategy for MPN patients by exploiting the synthetic lethality between germline mutations and the V617F MPN driver mutation. Myeloproliferative neoplasms (MPN) are rare hematologic disorders characterized by clonal hematopoiesis. Familial clustering is observed in a subset of cases, with a notable proportion exhibiting heterozygous germline mutations in DNA double-strand break repair genes (e.g., BRCA1). We investigated the therapeutic potential of targeting BRCA1 haploinsufficiency alongside the JAK2V617F driver mutation. We assessed the efficacy of combining the PARP inhibitor olaparib with interferon-alpha (IFNα) in CRISPR/Cas9-engineered Brca1+/- Jak2V617F-positive 32D cells. Olaparib treatment induced a higher number of DNA double-strand breaks, as demonstrated by γH2AX analysis through Western blot (p = 0.024), flow cytometry (p = 0.013), and confocal microscopy (p = 0.071). RAD51 foci formation was impaired in Brca1+/- cells compared to Brca1+/+ cells, indicating impaired homologous recombination repair due to Brca1 haploinsufficiency. Importantly, olaparib enhanced apoptosis while diminishing cell proliferation and viability in Brca1+/- cells compared to Brca1+/+ cells. These effects were further potentiated by IFNα. Olaparib induced interferon-stimulated genes and increased endogenous production of IFNα in Brca1+/- cells. These responses were abrogated by STING inhibition. In conclusion, our findings suggest that the combination of olaparib and IFNα presents a promising therapeutic strategy for MPN patients by exploiting the synthetic lethality between germline BRCA1 mutations and the JAK2V617F MPN driver mutation. |
| Author | Koschmieder, Steffen Bermes, Max Rodriguez, Maria Jimena Chatain, Nicolas Baumeister, Julian de Toledo, Marcelo Augusto Szymanski Müller-Newen, Gerhard Brümmendorf, Tim Henrik Ernst, Sabrina |
| Author_xml | – sequence: 1 givenname: Max surname: Bermes fullname: Bermes, Max organization: Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), 52074 Aachen, Germany – sequence: 2 givenname: Maria Jimena surname: Rodriguez fullname: Rodriguez, Maria Jimena organization: Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), 52074 Aachen, Germany – sequence: 3 givenname: Marcelo Augusto Szymanski orcidid: 0000-0003-4318-7381 surname: de Toledo fullname: de Toledo, Marcelo Augusto Szymanski organization: Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), 52074 Aachen, Germany – sequence: 4 givenname: Sabrina surname: Ernst fullname: Ernst, Sabrina organization: Confocal Microscopy Facility, Interdisciplinary Center for Clinical Research IZKF, RWTH Aachen University, 52074 Aachen, Germany – sequence: 5 givenname: Gerhard surname: Müller-Newen fullname: Müller-Newen, Gerhard organization: Department of Biochemistry, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany – sequence: 6 givenname: Tim Henrik orcidid: 0000-0002-9677-3723 surname: Brümmendorf fullname: Brümmendorf, Tim Henrik organization: Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), 52074 Aachen, Germany – sequence: 7 givenname: Nicolas orcidid: 0000-0003-4485-3120 surname: Chatain fullname: Chatain, Nicolas organization: Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), 52074 Aachen, Germany – sequence: 8 givenname: Steffen orcidid: 0000-0002-1011-8171 surname: Koschmieder fullname: Koschmieder, Steffen organization: Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), 52074 Aachen, Germany – sequence: 9 givenname: Julian orcidid: 0000-0001-6096-1952 surname: Baumeister fullname: Baumeister, Julian organization: Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), 52074 Aachen, Germany |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38139386$$D View this record in MEDLINE/PubMed |
| BookMark | eNpdkUuP0zAURi00iHnAki2yxIZNwI_EiZelmkehQDU8tpFjX09dOXbHToH8Cv4y6XQYAStbn46PfO93io5CDIDQc0pecy7JG7fpMytZSetKkEfohJaMFYSI-uiv-zE6zXlDCOOskk_QMW8ol7wRJ-jX-c-tj25w4QZ_HsOwhsFpvIRhrbwbRtzB8AMg4EtIvXcB8Nvr-YziK7V_FfLOWqcdBD1iFQxeza5XeBHWrpuMMWAX8LvZe_ZN0PqiWMU8pd8BfxjBx22K3llI6i76CHHrVe7zU_TYKp_h2f15hr5enH-ZXxXLT5eL-WxZ6JKJoQAwlvKGM6mZtpITRRmUVvFKdlqyGkTdlByYZY3m0hpFuLXKyEpronlN-RlaHLwmqk27Ta5XaWyjcu1dENNNq9K0Cg8tNZrURnVMK1NS2UkDAiglmgkJHSGT69XBNc10u4M8tL3LGrxXAeIut0ySqmKiIc2EvvwP3cRdCtOke6oUleRlNVHFgdIp5pzAPnyQknbfevtP6xP_4t6663owD_SfmvlvocarOA |
| CitedBy_id | crossref_primary_10_3390_ijms25115577 crossref_primary_10_1002_mog2_70 |
| Cites_doi | 10.1158/2159-8290.CD-18-1218 10.1172/JCI86892 10.1158/1541-7786.MCR-16-0108 10.3389/fphar.2022.912256 10.1182/blood-2009-12-259747 10.1038/leu.2013.102 10.1038/s41375-019-0629-z 10.1002/ijc.10109 10.1158/1078-0432.CCR-18-0179 10.1038/nature03445 10.1126/science.278.5340.1064 10.1182/blood-2008-01-134114 10.1186/s13045-016-0275-0 10.1007/s00277-019-03836-2 10.1016/j.immuni.2015.01.012 10.1182/blood-2012-05-432989 10.1200/JCO.2009.23.6075 10.1038/nature07815 10.1073/pnas.1110969108 10.1182/blood-2016-10-695957 10.1200/JCO.2016.67.0554 10.1586/ehm.11.63 10.2147/CMAR.S169558 10.1182/blood-2016-10-695940 10.1200/JCO.2007.12.6896 10.1182/bloodadvances.2021004811 10.1086/279847 10.1007/s12308-011-0096-6 10.1073/pnas.1401873111 10.1038/s41375-019-0638-y 10.1182/blood-2017-05-784942 10.1007/s002779900136 10.1038/nature03443 10.1126/science.1232458 10.32604/or.2023.028310 |
| ContentType | Journal Article |
| Copyright | 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7X7 7XB 88E 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH K9. M0S M1P M2O MBDVC PIMPY PQEST PQQKQ PQUKI Q9U 7X8 DOA |
| DOI | 10.3390/ijms242417560 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) ProQuest Health and Medical ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) ProQuest research library Research Library (Corporate) Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database Research Library Prep ProQuest Central Student ProQuest Central Basic ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Research Library (Alumni Edition) Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Research Library ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1422-0067 |
| ExternalDocumentID | oai_doaj_org_article_1dc07dab2cad419b9de6e110c269eb00 10_3390_ijms242417560 38139386 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: German Cancer Aid grantid: 70114726 |
| GroupedDBID | --- 29J 2WC 3V. 53G 5GY 5VS 7X7 88E 8FE 8FG 8FH 8FI 8FJ 8G5 A8Z AADQD AAFWJ AAHBH ABDBF ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ADBBV AEAQA AENEX AFKRA AFZYC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI CCPQU CGR CS3 CUY CVF D1I DIK DU5 DWQXO E3Z EBD EBS ECM EIF EJD ESTFP ESX F5P FRP FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 HCIFZ HH5 HMCUK HYE IAO ITC KB. KQ8 LK8 M1P M2O M48 M7P MODMG M~E NPM O5R O5S OK1 P2P PDBOC PIMPY PQQKQ PROAC PSQYO RIG RNS RPM TR2 TUS UKHRP ~8M AAYXX CITATION 7XB 8FK K9. MBDVC PQEST PQUKI Q9U 7X8 |
| ID | FETCH-LOGICAL-c426t-eedf138329c2cf930a12e4fa359bc927e67843e2f28c39fda03ffad95cc0c3713 |
| IEDL.DBID | DOA |
| ISSN | 1422-0067 1661-6596 |
| IngestDate | Tue Oct 22 15:01:13 EDT 2024 Fri Oct 25 06:36:32 EDT 2024 Fri Nov 08 21:37:18 EST 2024 Thu Nov 21 21:21:56 EST 2024 Sat Nov 02 12:26:19 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 24 |
| Keywords | myeloproliferative neoplasms IFNα haploinsufficiency homologous recombination repair olaparib synthetic lethality interferon-alpha MPN BRCA1 DNA repair |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c426t-eedf138329c2cf930a12e4fa359bc927e67843e2f28c39fda03ffad95cc0c3713 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0003-4485-3120 0000-0002-9677-3723 0000-0001-6096-1952 0000-0002-1011-8171 0000-0003-4318-7381 |
| OpenAccessLink | https://doaj.org/article/1dc07dab2cad419b9de6e110c269eb00 |
| PMID | 38139386 |
| PQID | 2904659345 |
| PQPubID | 2032341 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_1dc07dab2cad419b9de6e110c269eb00 proquest_miscellaneous_2905526808 proquest_journals_2904659345 crossref_primary_10_3390_ijms242417560 pubmed_primary_38139386 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-Dec-16 |
| PublicationDateYYYYMMDD | 2023-12-16 |
| PublicationDate_xml | – month: 12 year: 2023 text: 2023-Dec-16 day: 16 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland – name: Basel |
| PublicationTitle | International journal of molecular sciences |
| PublicationTitleAlternate | Int J Mol Sci |
| PublicationYear | 2023 |
| Publisher | MDPI AG |
| Publisher_xml | – name: MDPI AG |
| References | Farmer (ref_8) 2005; 434 Li (ref_16) 2010; 116 Deeg (ref_4) 2014; 18 Kantarjian (ref_19) 2009; 27 Sun (ref_23) 2013; 339 Poh (ref_22) 2019; 25 Rumi (ref_5) 2007; 25 Nambiar (ref_31) 2023; 31 Maxwell (ref_24) 2016; 34 Elbracht (ref_7) 2021; 5 Corrales (ref_29) 2016; 126 Plo (ref_17) 2008; 112 Chen (ref_14) 2014; 111 Essers (ref_26) 2009; 458 Bridges (ref_10) 1922; 56 Austin (ref_21) 2020; 34 Buchholz (ref_12) 2002; 97 Rumi (ref_6) 2017; 129 Hartwell (ref_11) 1997; 278 Maifrede (ref_28) 2017; 130 Kreipe (ref_3) 2011; 4 Vainchenker (ref_1) 2017; 129 Konishi (ref_13) 2011; 108 Brodmann (ref_2) 2000; 79 Bryant (ref_9) 2005; 434 Hasselbalch (ref_25) 2011; 4 Baumeister (ref_35) 2020; 34 Mullally (ref_20) 2013; 121 Zhao (ref_34) 2022; 13 Erttmann (ref_18) 2015; 42 Kirschner (ref_27) 2019; 98 Marty (ref_15) 2013; 27 Guo (ref_32) 2018; 10 McMahon (ref_33) 2016; 14 Han (ref_36) 2016; 9 Pantelidou (ref_30) 2019; 9 |
| References_xml | – volume: 9 start-page: 722 year: 2019 ident: ref_30 article-title: Parp Inhibitor Efficacy Depends on CD8+ T-Cell Recruitment via Intratumoral Sting Pathway Activation in Brca-Deficient Models of Triple-Negative Breast Cancer publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-18-1218 contributor: fullname: Pantelidou – volume: 126 start-page: 2404 year: 2016 ident: ref_29 article-title: The Host STING Pathway at the Interface of Cancer and Immunity publication-title: J. Clin. Investig. doi: 10.1172/JCI86892 contributor: fullname: Corrales – volume: 14 start-page: 1195 year: 2016 ident: ref_33 article-title: Olaparib, Monotherapy or with Ionizing Radiation, Exacerbates DNA Damage in Normal Tissues: Insights from a New P21 Reporter Mouse publication-title: Mol. Cancer Res. doi: 10.1158/1541-7786.MCR-16-0108 contributor: fullname: McMahon – volume: 13 start-page: 912256 year: 2022 ident: ref_34 article-title: Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data publication-title: Front. Pharmacol. doi: 10.3389/fphar.2022.912256 contributor: fullname: Zhao – volume: 116 start-page: 1528 year: 2010 ident: ref_16 article-title: JAK2 V617F Impairs Hematopoietic Stem Cell Function in a Conditional Knock-in Mouse Model of JAK2 V617F-Positive Essential Thrombocythemia publication-title: Blood doi: 10.1182/blood-2009-12-259747 contributor: fullname: Li – volume: 27 start-page: 2187 year: 2013 ident: ref_15 article-title: A Role for Reactive Oxygen Species in JAK2 V617F Myeloproliferative Neoplasm Progression publication-title: Leukemia doi: 10.1038/leu.2013.102 contributor: fullname: Marty – volume: 34 start-page: 1062 year: 2020 ident: ref_35 article-title: Hypoxia-Inducible Factor 1 (HIF-1) Is a New Therapeutic Target in JAK2V617F-Positive Myeloproliferative Neoplasms publication-title: Leukemia doi: 10.1038/s41375-019-0629-z contributor: fullname: Baumeister – volume: 97 start-page: 557 year: 2002 ident: ref_12 article-title: Evidence of Haplotype Insufficiency in Human Cells Containing a Germline Mutation in BRCA1 or BRCA2 publication-title: Int. J. Cancer doi: 10.1002/ijc.10109 contributor: fullname: Buchholz – volume: 25 start-page: 2513 year: 2019 ident: ref_22 article-title: BRCA1 Promoter Methylation Is Linked to Defective Homologous Recombination Repair and Elevated MiR-155 to Disrupt Myeloid Differentiation in Myeloid Malignancies publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-18-0179 contributor: fullname: Poh – volume: 434 start-page: 917 year: 2005 ident: ref_8 article-title: Targeting the DNA Repair Defect in BRCA Mutant Cells as a Therapeutic Strategy publication-title: Nature doi: 10.1038/nature03445 contributor: fullname: Farmer – volume: 278 start-page: 1064 year: 1997 ident: ref_11 article-title: Integrating Genetic Approaches into the Discovery of Anticancer Drugs publication-title: Science doi: 10.1126/science.278.5340.1064 contributor: fullname: Hartwell – volume: 112 start-page: 1402 year: 2008 ident: ref_17 article-title: JAK2 Stimulates Homologous Recombination and Genetic Instability: Potential Implication in the Heterogeneity of Myeloproliferative Disorders publication-title: Blood doi: 10.1182/blood-2008-01-134114 contributor: fullname: Plo – volume: 9 start-page: 45 year: 2016 ident: ref_36 article-title: Calreticulin-Mutant Proteins Induce Megakaryocytic Signaling to Transform Hematopoietic Cells and Undergo Accelerated Degradation and Golgi-Mediated Secretion publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-016-0275-0 contributor: fullname: Han – volume: 98 start-page: 2703 year: 2019 ident: ref_27 article-title: Transcriptional Alteration of DNA Repair Genes in Philadelphia Chromosome Negative Myeloproliferative Neoplasms publication-title: Ann. Hematol. doi: 10.1007/s00277-019-03836-2 contributor: fullname: Kirschner – volume: 42 start-page: 332 year: 2015 ident: ref_18 article-title: DNA Damage Primes the Type I Interferon System via the Cytosolic DNA Sensor STING to Promote Anti-Microbial Innate Immunity publication-title: Immunity doi: 10.1016/j.immuni.2015.01.012 contributor: fullname: Erttmann – volume: 121 start-page: 3692 year: 2013 ident: ref_20 article-title: Depletion of Jak2V617F Myeloproliferative Neoplasm-Propagating Stem Cells by Interferon-α in a Murine Model of Polycythemia Vera publication-title: Blood doi: 10.1182/blood-2012-05-432989 contributor: fullname: Mullally – volume: 27 start-page: 5418 year: 2009 ident: ref_19 article-title: Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients with Advanced Essential Thrombocythemia and Polycythemia Vera publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2009.23.6075 contributor: fullname: Kantarjian – volume: 18 start-page: 1023 year: 2014 ident: ref_4 article-title: Role of HSCT in Patients with MPD publication-title: Hematol. Oncol. Clin. N. Am. contributor: fullname: Deeg – volume: 458 start-page: 904 year: 2009 ident: ref_26 article-title: IFNα Activates Dormant Haematopoietic Stem Cells in Vivo publication-title: Nature doi: 10.1038/nature07815 contributor: fullname: Essers – volume: 108 start-page: 17773 year: 2011 ident: ref_13 article-title: Mutation of a Single Allele of the Cancer Susceptibility Gene BRCA1 Leads to Genomic Instability in Human Breast Epithelial Cells publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.1110969108 contributor: fullname: Konishi – volume: 129 start-page: 680 year: 2017 ident: ref_6 article-title: Diagnosis, Risk Stratification, and Response Evaluation in Classical Myeloproliferative Neoplasms publication-title: Blood doi: 10.1182/blood-2016-10-695957 contributor: fullname: Rumi – volume: 34 start-page: 4183 year: 2016 ident: ref_24 article-title: Population Frequency of Germline BRCA1/2 Mutations publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2016.67.0554 contributor: fullname: Maxwell – volume: 4 start-page: 637 year: 2011 ident: ref_25 article-title: A New Era for IFN-α in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms publication-title: Expert Rev. Hematol. doi: 10.1586/ehm.11.63 contributor: fullname: Hasselbalch – volume: 10 start-page: 2553 year: 2018 ident: ref_32 article-title: The Efficacy and Safety of Olaparib in the Treatment of Cancers: A Meta-Analysis of Randomized Controlled Trials publication-title: Cancer Manag. Res. doi: 10.2147/CMAR.S169558 contributor: fullname: Guo – volume: 129 start-page: 667 year: 2017 ident: ref_1 article-title: Genetic Basis and Molecular Pathophysiology of Classical Myeloproliferative Neoplasms publication-title: Blood doi: 10.1182/blood-2016-10-695940 contributor: fullname: Vainchenker – volume: 25 start-page: 5630 year: 2007 ident: ref_5 article-title: Familial Chronic Myeloproliferative Disorders: Clinical Phenotype and Evidence of Disease Anticipation publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2007.12.6896 contributor: fullname: Rumi – volume: 5 start-page: 3373 year: 2021 ident: ref_7 article-title: Germline Variants in DNA Repair Genes, Including BRCA1/2, May Cause Familial Myeloproliferative Neoplasms publication-title: Blood Adv. doi: 10.1182/bloodadvances.2021004811 contributor: fullname: Elbracht – volume: 56 start-page: 51 year: 1922 ident: ref_10 article-title: The Origin of Variations in Sexual and Sex-Limited Characters publication-title: Am. Nat. doi: 10.1086/279847 contributor: fullname: Bridges – volume: 4 start-page: 61 year: 2011 ident: ref_3 article-title: Progression of Myeloproliferative Neoplasms to Myelofibrosis and Acute Leukaemia publication-title: J. Hematop. doi: 10.1007/s12308-011-0096-6 contributor: fullname: Kreipe – volume: 111 start-page: 15190 year: 2014 ident: ref_14 article-title: JAK2V617F Promotes Replication Fork Stalling with Disease-Restricted Impairment of the Intra-S Checkpoint Response publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.1401873111 contributor: fullname: Chen – volume: 34 start-page: 1075 year: 2020 ident: ref_21 article-title: Distinct Effects of Ruxolitinib and Interferon-Alpha on Murine JAK2V617F Myeloproliferative Neoplasm Hematopoietic Stem Cell Populations publication-title: Leukemia doi: 10.1038/s41375-019-0638-y contributor: fullname: Austin – volume: 130 start-page: 2848 year: 2017 ident: ref_28 article-title: Ruxolitinib-Induced Defects in DNA Repair Cause Sensitivity to PARP Inhibitors in Myeloproliferative Neoplasms publication-title: Blood doi: 10.1182/blood-2017-05-784942 contributor: fullname: Maifrede – volume: 79 start-page: 312 year: 2000 ident: ref_2 article-title: Myeloproliferative Disorders: Complications, Survival and Causes of Death publication-title: Ann. Hematol. doi: 10.1007/s002779900136 contributor: fullname: Brodmann – volume: 434 start-page: 913 year: 2005 ident: ref_9 article-title: Specific Killing of BRCA2-Deficient Tumours with Inhibitors of Poly(ADP-Ribose) Polymerase publication-title: Nature doi: 10.1038/nature03443 contributor: fullname: Bryant – volume: 339 start-page: 786 year: 2013 ident: ref_23 article-title: Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway publication-title: Science doi: 10.1126/science.1232458 contributor: fullname: Sun – volume: 31 start-page: 405 year: 2023 ident: ref_31 article-title: Targeting DNA Repair for Cancer Treatment: Lessons from PARP Inhibitor Trials publication-title: Oncol. Res. doi: 10.32604/or.2023.028310 contributor: fullname: Nambiar |
| SSID | ssj0023259 |
| Score | 2.4500353 |
| Snippet | Myeloproliferative neoplasms (MPN) are rare hematologic disorders characterized by clonal hematopoiesis. Familial clustering is observed in a subset of cases,... |
| SourceID | doaj proquest crossref pubmed |
| SourceType | Open Website Aggregation Database Index Database |
| StartPage | 17560 |
| SubjectTerms | Apoptosis BRCA1 BRCA1 Protein - genetics Breast cancer Cell cycle Cell growth DNA DNA damage Flow cytometry Germ Cells Haploinsufficiency Humans Interferon interferon-alpha Interferon-alpha - pharmacology Kinases Medical prognosis Metabolism Mortality MPN Mutation Myeloproliferative Disorders - drug therapy Myeloproliferative Disorders - genetics myeloproliferative neoplasms Neoplasms - drug therapy olaparib Ovarian cancer Poly(ADP-ribose) Polymerase Inhibitors - pharmacology Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use Recombinational DNA Repair Stem cells Synthetic Lethal Mutations Tumors |
| Title | Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38139386 https://www.proquest.com/docview/2904659345 https://search.proquest.com/docview/2905526808 https://doaj.org/article/1dc07dab2cad419b9de6e110c269eb00 |
| Volume | 24 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NT9wwELVaJKReqrb0Iy1FRqp6i3BsJ7GPC2VZoEUraKveIscfYpEwiOxW2l_Rv9wZJ7tVD4gLtyhxIssz9ptxnt8Q8klJVwbJHe7a1LnUyuUts3gVGLiHryuPZ4cnF_XZL_XlEGVy1qW-kBPWywP3A7dXOMtqZ1pujZOFbrXzlQfMsrzSWPcmrb6sWiVTQ6oleCqTVgD65FWpq15dU0CCvze7uu7wTATgZtKl_IdGSbT__kgzIc74BXk-hIp01HfxJXni4yuy2RePXG6RP4k-N0PaMr1YRgjkoB396ueXKbSmAwOLHsHai7Ek3T8_GBV0YvCt2C2SdgQevKQmOjodnU_pcbyctYnDRWeRnoxO-U8IPcb5NDG7fnv6bYkMIyz0E3wvGU7PkIJuuuvuNfkxPvx-MMmH8gq5BVie54COoYAElWvLbdCCmYJ7GYwodWs1rz3gmBSeB66s0MEZJkIwTpfWMisguX1DNuJN9O8I9SXmHU6KVgbZttoYWXslA3xQGSVlRj6vhrm57VU0Gsg-0B7Nf_bIyD4aYd0Ixa_TDXCJZnCJ5iGXyMj2yoTNMCO7hmsmwROELDOyu34Mcwl_kJjobxapTYnyN0xl5G1v-nVPILIRWqjq_WP08AN5hmXrkRZTVNtkY3638B_J084tdsCPj093kjf_Bc1x-NQ |
| link.rule.ids | 315,782,786,866,2106,27933,27934 |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Exploiting+Synthetic+Lethality+between+Germline+BRCA1+Haploinsufficiency+and+PARP+Inhibition+in+JAK2V617F-Positive+Myeloproliferative+Neoplasms&rft.jtitle=International+journal+of+molecular+sciences&rft.au=Bermes%2C+Max&rft.au=Rodriguez%2C+Maria+Jimena&rft.au=de+Toledo%2C+Marcelo+Augusto+Szymanski&rft.au=Ernst%2C+Sabrina&rft.date=2023-12-16&rft.eissn=1422-0067&rft.volume=24&rft.issue=24&rft_id=info:doi/10.3390%2Fijms242417560&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1422-0067&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1422-0067&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1422-0067&client=summon |